Skip to main
DVAX

Dynavax Technologies (DVAX) Stock Forecast & Price Target

Dynavax Technologies (DVAX) Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 25%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 25%

Bulls say

Dynavax Technologies Corp demonstrates a strong positive outlook due to its promising vaccine candidates, particularly the shingles vaccine, which has shown vaccine response rates comparable to that of Shingrix while exhibiting significantly better tolerability. The encouraging results regarding immunogenicity and tolerability align well with management's expectations, further solidifying the company’s position in the biopharmaceutical market. Additionally, the robust revenue generation from its existing products, CpG 1018 and HEPLISAV-B, underscores the company's financial stability and growth potential in the vaccination sector.

Bears say

Dynavax Technologies faces a negative outlook primarily due to the high risk associated with its clinical candidates, which may fail to demonstrate efficacy or pose safety concerns that could hinder regulatory approval and commercialization. Additionally, the company may encounter challenges in effectively commercializing its products due to adverse market conditions, intense competition, and potential difficulties in securing favorable partnership agreements. Furthermore, litigation risks could further complicate Dynavax's ability to navigate the competitive landscape and achieve successful product launches.

Dynavax Technologies (DVAX) has been analyzed by 4 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 25% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dynavax Technologies (DVAX) Forecast

Analysts have given Dynavax Technologies (DVAX) a Hold based on their latest research and market trends.

According to 4 analysts, Dynavax Technologies (DVAX) has a Hold consensus rating as of Feb 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dynavax Technologies (DVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.